CN112076112B - Oral care composition comprising stable stannous ions - Google Patents
Oral care composition comprising stable stannous ions Download PDFInfo
- Publication number
- CN112076112B CN112076112B CN201910506957.6A CN201910506957A CN112076112B CN 112076112 B CN112076112 B CN 112076112B CN 201910506957 A CN201910506957 A CN 201910506957A CN 112076112 B CN112076112 B CN 112076112B
- Authority
- CN
- China
- Prior art keywords
- hyaluronic acid
- stannous
- oral care
- ion source
- care composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 150000002500 ions Chemical class 0.000 title claims abstract description 37
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 83
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 82
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 82
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 claims abstract description 62
- ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical compound F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 claims description 10
- 229960002799 stannous fluoride Drugs 0.000 claims description 10
- 150000003839 salts Chemical group 0.000 claims description 8
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims description 6
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 6
- 239000001119 stannous chloride Substances 0.000 claims description 6
- 235000011150 stannous chloride Nutrition 0.000 claims description 6
- 239000000606 toothpaste Substances 0.000 claims description 5
- 229940034610 toothpaste Drugs 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000002324 mouth wash Substances 0.000 claims description 3
- 229940051866 mouthwash Drugs 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 description 8
- 239000004094 surface-active agent Substances 0.000 description 7
- 239000002562 thickening agent Substances 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000004075 cariostatic agent Substances 0.000 description 5
- 239000003906 humectant Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 235000010418 carrageenan Nutrition 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- YXTDAZMTQFUZHK-ZVGUSBNCSA-L (2r,3r)-2,3-dihydroxybutanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O YXTDAZMTQFUZHK-ZVGUSBNCSA-L 0.000 description 3
- CKUJRAYMVVJDMG-IYEMJOQQSA-L (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;tin(2+) Chemical compound [Sn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O CKUJRAYMVVJDMG-IYEMJOQQSA-L 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- PNOXNTGLSKTMQO-UHFFFAOYSA-L diacetyloxytin Chemical compound CC(=O)O[Sn]OC(C)=O PNOXNTGLSKTMQO-UHFFFAOYSA-L 0.000 description 3
- -1 fluoride ions Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229940007163 stannous tartrate Drugs 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- RCIVOBGSMSSVTR-UHFFFAOYSA-L stannous sulfate Chemical compound [SnH2+2].[O-]S([O-])(=O)=O RCIVOBGSMSSVTR-UHFFFAOYSA-L 0.000 description 2
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 description 2
- 229910000375 tin(II) sulfate Inorganic materials 0.000 description 2
- QHGNHLZPVBIIPX-UHFFFAOYSA-N tin(ii) oxide Chemical compound [Sn]=O QHGNHLZPVBIIPX-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- OQBLGYCUQGDOOR-UHFFFAOYSA-L 1,3,2$l^{2}-dioxastannolane-4,5-dione Chemical compound O=C1O[Sn]OC1=O OQBLGYCUQGDOOR-UHFFFAOYSA-L 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- GEZAUFNYMZVOFV-UHFFFAOYSA-J 2-[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetan-2-yl)oxy]-1,3,2$l^{5},4$l^{2}-dioxaphosphastannetane 2-oxide Chemical compound [Sn+2].[Sn+2].[O-]P([O-])(=O)OP([O-])([O-])=O GEZAUFNYMZVOFV-UHFFFAOYSA-J 0.000 description 1
- USYAMXSCYLGBPT-UHFFFAOYSA-L 3-carboxy-3-hydroxypentanedioate;tin(2+) Chemical compound [Sn+2].OC(=O)CC(O)(C([O-])=O)CC([O-])=O USYAMXSCYLGBPT-UHFFFAOYSA-L 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 239000003082 abrasive agent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000675 anti-caries Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000003975 dentin desensitizing agent Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000002701 inhibitory effect on caries Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011742 magnesium glycerophosphate Substances 0.000 description 1
- 235000001130 magnesium glycerophosphate Nutrition 0.000 description 1
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- COALSIYJQHMCDX-UHFFFAOYSA-L propanedioate;tin(2+) Chemical compound [Sn+2].[O-]C(=O)CC([O-])=O COALSIYJQHMCDX-UHFFFAOYSA-L 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to an oral care composition comprising stable stannous ions, characterized in that it comprises: a stannous ion source, hyaluronic acid and an orally acceptable carrier; and the mass ratio of the stannous ion source to the hyaluronic acid is 1:10-10:1. In the oral care compositions of the present invention, a particular proportion of hyaluronic acid can provide a substantial increase in the stability of the stannous ion source in the composition.
Description
Technical Field
The invention relates to the technical field of oral care, in particular to an oral care composition containing stable stannous ions.
Background
Stannous ions have a long history of use in oral care products. Early stannous ions were added to the oral care composition in the form of stannous fluoride for providing fluoride ions; then, stannous ions are gradually discovered to have the functions of antibiosis, sensitization resistance, ore removal prevention and the like.
The use of stannous ions in oral care compositions is numerous, for example, chinese patent publication No. CN 104853715A discloses an aqueous oral care composition comprising a water-soluble stannous ion source, wherein the composition comprises at least 50wt% water, and wherein the stannous ion source is selected from the group consisting of stannous chloride, stannous pyrophosphate, stannous formate, stannous acetate, stannous gluconate, stannous lactate, stannous tartrate, stannous oxalate, stannous malonate, stannous citrate, stannous glyoxylate, and mixtures thereof. The oral care composition has greatly improved robustness against microbial challenges. I.e., to give the oral care composition robustness against microbial challenges.
For another example, chinese patent publication No. CN 104069013A discloses an oral composition comprising a stannous ion source, a multivalent cation source, and a mineral surfactant, which provides enhanced therapeutic efficacy from stannous fluoride and/or other stannous salts, including antimicrobial efficacy, inhibiting bad breath, inhibiting plaque growth and metabolism, reducing gingivitis, slowing the progression of periodontal disease, reducing dentinal hypersensitivity, and reducing crowns and root dental caries.
For another example, chinese patent publication No. CN 106074192A discloses an oral care composition comprising a polyphenolic compound, a stannous ion source, and a soluble alkaline earth metal ion source, wherein the alkaline earth metal ion source is a non-antioxidant. In the oral care composition, stannous ions reduce oxidation of the polyphenolic compounds in the composition.
The above are all effective examples of stannous ion use. However, divalent stannous ions added to oral care composition species are easily oxidized, especially in aqueous environments, to tetravalent stannous oxide or tin oxide precipitates, which not only affects the bioavailability of stannous ions, but also the stability of the composition itself.
Hyaluronic acid is an acidic mucopolysaccharide, which was first isolated from bovine vitreous humor by professor Meyer, university of columbia, us 1934, and also widely distributed in various parts of the human body.
Disclosure of Invention
The technical problem to be solved by the present invention is to provide an oral care composition comprising stable stannous ions. In the oral care composition, the stability of the stannous ion source in the composition can be greatly improved by the hyaluronic acid with a specific proportion.
In order to solve the technical problems, the invention adopts the following technical scheme:
an oral care composition comprising stable stannous ions comprising
A source of stannous ions, which is selected from the group consisting of,
Hyaluronic acid
An orally acceptable carrier; and is also provided with
The mass ratio of the stannous ion source to the hyaluronic acid is 1:10-10:1.
Preferably, the mass ratio of the stannous ion source to the hyaluronic acid is 1:1-10:1; more preferably, the mass ratio of the stannous ion source to hyaluronic acid is 1:3-10:1.
As a further improvement of the technical scheme, the adding amount of the stannous ion source in the oral care composition is 0.05% -3%; preferably, the stannous ion source is added to the oral care composition in an amount of 0.1% -3%; more preferably, the stannous ion source is added to the oral care composition in an amount of from 0.5% to 3%; most preferably, the stannous ion source is added to the oral care composition in an amount of 1% -3%.
As a further improvement of the technical scheme, the addition amount of the hyaluronic acid in the oral care composition is 0.05-5%; preferably, the hyaluronic acid is added to the oral care composition in an amount of 0.1-5%; more preferably, the hyaluronic acid is added to the oral care composition in an amount of 0.5-5%; most preferably, the hyaluronic acid is added to the oral care composition in an amount of 1-5%.
As a further improvement of the technical scheme, the stannous ion source is selected from one or more of stannous fluoride, stannous chloride, stannous acetate, stannous gluconate, stannous sulfate, stannous lactate and stannous tartrate;
Preferably, the stannous ion source is selected from stannous fluoride or stannous chloride.
As a further improvement of the technical scheme, the molecular formula of the hyaluronic acid is (C 14H21NO11) n, and the hyaluronic acid has the following structural formula:
Preferably, the hyaluronic acid comprises an acid form of hyaluronic acid or a salt form of hyaluronic acid; the salt forms of hyaluronic acid include, for example, sodium hyaluronate and the like.
Preferably, the hyaluronic acid is selected from low molecular weight hyaluronic acid, medium molecular weight hyaluronic acid or high molecular weight hyaluronic acid.
Preferably, the low molecular weight hyaluronic acid has a molecular weight in the range of 10kDa-1000kDa, preferably 200kDa-400kDa; the molecular weight of the medium molecular weight hyaluronic acid ranges from 1000kDa to 1800kDa; the high molecular weight hyaluronic acid has a molecular weight in the range of more than 1800kDa, preferably 1900kDa-2400kDa.
As a further improvement of the technical solution, the oral care composition comprises a toothpaste, gel, mouthwash or dentifrice.
Any range recited in the invention includes any numerical value between the endpoints and any sub-range of any numerical value between the endpoints or any numerical value between the endpoints.
Unless otherwise indicated, all starting materials herein are commercially available, and the equipment used in the present invention may be conventional in the art or may be conventional in the art.
Compared with the prior art, the invention has the following beneficial effects:
the oral care composition contains stannous ions, and the stability of a stannous ion source in the composition can be greatly improved by adding hyaluronic acid in a specific proportion.
Detailed Description
In order to more clearly illustrate the present invention, the present invention will be further described with reference to preferred embodiments. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and that this invention is not limited to the details given herein.
As one aspect of the invention, an oral care composition comprising stabilized stannous ions of the invention comprises
A source of stannous ions, which is selected from the group consisting of,
Hyaluronic acid
An orally acceptable carrier; and is also provided with
The mass ratio of the stannous ion source to the hyaluronic acid is 1:10-10:1.
In certain embodiments of the invention, the mass ratio of the stannous ion source to hyaluronic acid is 1:9-10:1,1:8-10:1,1:5-10:1,1:3-10:1,1:1-10:1,1:10-9:1,1:10-8:1,1:10-5:1,1:10-3:1,1:10-1:1,1：9-9:1,1:8-8:1,1:7-7:1,1:5-5:1,1:3-3:1;
In certain preferred embodiments of the invention, the mass ratio of stannous ion source to hyaluronic acid is 1:3-10:1.
The present inventors have unexpectedly found that the stability of stannous ions can be significantly improved by the addition of hyaluronic acid in the specific proportions described above in oral care compositions containing a source of stannous ions.
In certain embodiments of the present invention, the stannous ion source is added to the oral care composition in an amount of from 0.01 to 3%, preferably in an amount of from 0.05% to 3%, more preferably in an amount of 0.1％-3％,0.2-3％,0.5％-3％,1％-3％,2％-3％,0.01％-2.5％,0.05％-2.5％,0.1％-2.5％,0.2％-2％,0.5％-2％,0.5％-1.5％,0.5％-1％.
In certain embodiments of the present invention, the hyaluronic acid is added to the oral care composition in an amount of 0.01-3%, preferably in an amount of 0.05% -3%, more preferably in an amount of 0.1％-3％,0.2-3％,0.5％-3％,1％-3％,2％-3％,0.01％-2.5％,0.05％-2.5％,0.1％-2.5％,0.2％-2％,0.5％-2％,0.5％-1.5％,0.5％-1％.
In certain embodiments of the present invention, the stannous ion source is selected from one or more of stannous fluoride, stannous chloride, stannous acetate, stannous gluconate, stannous sulfate, stannous lactate, and stannous tartrate.
In certain preferred embodiments of the present invention, the stannous ion source is selected from stannous fluoride or stannous chloride.
Hyaluronic acid is also called uronic acid and hyaluronic acid (Hyaluronan) and is widely distributed on various parts of a human body; the high polymer polysaccharide consists of D-glucuronic acid and N-acetylglucosamine, wherein the D-glucuronic acid and the N-acetylglucosamine are connected by beta-1, 3-glycosidic bond, the disaccharide units are connected by beta-1, 4-glycosidic bond, and the disaccharide units can reach as much as 25000.
In certain embodiments of the invention, the hyaluronic acid has the formula (C 14H21NO11) n, having the formula:
in certain embodiments of the invention, the hyaluronic acid comprises an acid form of hyaluronic acid or a salt form of hyaluronic acid. The salt forms of hyaluronic acid include, for example, sodium hyaluronate and the like.
In certain preferred embodiments of the present invention, the hyaluronic acid is selected from low molecular weight hyaluronic acid, medium molecular weight hyaluronic acid or high molecular weight hyaluronic acid.
In certain preferred embodiments of the invention, the low molecular weight hyaluronic acid has a molecular weight in the range of 10kDa-1000kDa, preferably 200kDa-400kDa; the molecular weight of the medium molecular weight hyaluronic acid ranges from 1000kDa to 1800kDa; the high molecular weight hyaluronic acid has a molecular weight in the range of more than 1900kDa, preferably 1800kDa-2400kDa.
In certain embodiments of the present invention, the oral care composition comprises a toothpaste, gel, mouthwash, or tooth powder.
In the present invention, the "orally acceptable carrier" refers to any vehicle suitable for formulating the disclosed oral care compositions; an orally acceptable carrier is not harmful to a mammal when retained in the mouth in the amounts disclosed herein without swallowing for a period of time sufficient to allow effective contact with the tooth surfaces as required by the present invention; generally, an orally acceptable carrier is not harmful even if inadvertently swallowed; suitable orally acceptable carriers include, for example, one or more of the following: water, thickening agents, buffers, humectants, surfactants, abrasives, sweeteners, flavoring agents, vision aids (e.g., pigments, dyes, or mixtures thereof), anticaries agents, antibacterial agents, whitening agents, desensitizing agents, vitamins, preservatives, enzymes, mixtures thereof, and the like.
In certain preferred embodiments of the present invention, the oral care composition includes humectant, thickener, and/or surfactant adjuvants.
"Humectant" is an ingredient that prevents the dehydration and hardening of an oral care composition. Exemplary humectants include, but are not limited to, for example, glycerin, propylene glycol, sorbitol, and the like. The humectant is typically present in the oral care composition in an amount of from 10 to 80% by mass.
A "thickener" is a substance that increases the viscosity of a solution or liquid/solid mixture, but does not substantially change its properties. The purpose of the thickener is to provide the product with a skeleton, flowability and stability. Exemplary thickeners include, but are not limited to, one or more of hydroxyethylcellulose, carboxymethylcellulose and salts thereof (e.g., sodium carboxymethylcellulose), carrageenan (carrageenan), carboxyvinyl polymers, xanthan gum (xanthan g μm), carrageenan, gelatin, pullulan, sodium alginate, and the like. In certain embodiments, the thickening agent comprises one or more of xanthan gum, carrageenan, or sodium carboxymethyl cellulose. The weight proportion of thickener in the oral care composition is typically from 0.2 to 2%.
The "surfactant" serves the purpose of emulsifying the flavour and foaming in the oral care composition and may assist in some degree in the adequate and complete dispersion of the hydroxyapatite-polycarboxy compound complex. Exemplary surfactants include, but are not limited to, anionic surfactants such as sodium dodecyl sulfate; amphoteric surfactants such as betaine; amino acid surfactants such as sodium lauroyl sarcosinate and nonionic surfactants. The weight proportion of surfactant in the oral care composition is typically from 0.5 to 2.5%.
According to certain preferred embodiments of the present application, the oral care composition may further comprise active ingredients such as antibacterial agents, anticaries agents, antiallergic agents, and/or whitening agents.
"Antibacterial agent" refers to a chemical substance that is capable of maintaining the growth or proliferation of certain microorganisms in an oral care composition below a requisite level for a period of time. Exemplary antimicrobial agents include, but are not limited to: tetrahydrocurcumin, cetylpyridinium chloride, triclosan, and the like.
"Anticaries agent" refers to a substance that has an inhibitory effect on caries, such as a substance that can enhance the anticaries ability of the tooth by reducing the solubility of hydroxyapatite of the enamel, or a substance that controls plaque, inhibits bacterial growth. Exemplary anticaries agents include, but are not limited to, phosphorous-containing agents (calcium phosphate, magnesium glycerophosphate, milk calcium phosphate, sodium caseinate, etc.), or arginine and derivatives thereof. Preferably, in certain embodiments, the anticaries agent comprises a fluoride ion source.
"Antiallergic agent" means a substance capable of preventing or treating dentinal hypersensitivity by inhibiting nerve impulse or by blocking dentinal tubules or reducing its permeability. Exemplary anti-sensitizers include, but are not limited to: dipotassium glycyrrhizinate, potassium fluoride, potassium nitrate, potassium chloride and other potassium ion sources.
"Whitening agent" refers to a substance that has a whitening effect on teeth. Exemplary whitening agents include, but are not limited to: peroxide bleaches.
Examples 1-4, comparative example 1:
an oral care composition comprising stable stannous ions comprising the ingredients in the weight proportions of table 1 below, in total amounts of 100 parts.
Table 1:
After the compositions of examples 1 to 4 and comparative example 1 were left at room temperature for 7 days, the remaining stannous fluoride content of the composition solution was measured, and the data are shown in Table 2 below.
Table 2:
As can be seen from tables 1 and 2 above, in the composition containing stannous ions, the stability of stannous ions was low when hyaluronic acid was not added, and the remaining stannous ion source was less than 30% by mass after 7 days of standing; when the mass ratio of the stannous ion source to the hyaluronic acid is less than or equal to 1:1, the stability of stannous ions is obviously improved, and after the stannous ion source is placed for 7 days, the remaining stannous ion source is more than 50% of the mass ratio; when the mass ratio of the stannous ion source to the hyaluronic acid is less than or equal to 1:3, the stability of stannous ions is more obviously improved, and after the stannous ion source is placed for 7 days, the remaining stannous ion source is more than 65% by mass; when the mass ratio of the stannous ion source to the hyaluronic acid is less than or equal to 1:5, the stability of stannous ions is more obviously improved, and after the stannous ion source is placed for 7 days, the remaining stannous ion source is more than 75% by mass; however, after the mass ratio of the stannous ion source to the hyaluronic acid is less than or equal to 1:5, the stability improvement ratio of the stannous ion does not continue to obviously improve even if the adding amount of the hyaluronic acid is increased.
In the invention, the detection method of stannous ion adopts the detection method of the chemical industry standard HG/T2526-2007 stannous ion.
Examples 5-8, comparative example 2:
An oral care composition comprising stable stannous ions comprising the ingredients in the weight proportions of table 3 below, in total amounts of 100 parts.
Table 3:
after the compositions of examples 5 to 8 and comparative example 2 were left at room temperature for 7 days, the remaining stannous fluoride content of the composition solution was measured, and the data are shown in Table 4 below:
As can be seen from tables 3 and 4 above, in the composition containing stannous ions, the stability of stannous ions was low when hyaluronic acid was not added, and the remaining stannous ion source was less than 30% by mass after 7 days of standing; when the mass ratio of the stannous ion source to the hyaluronic acid is less than or equal to 10:1, the stability of stannous ions is obviously improved, and after the stannous ion source is placed for 7 days, the remaining stannous ion source is more than 45% of the mass ratio; when the mass ratio of the stannous ion source to the hyaluronic acid is less than or equal to 3:1, the stability of stannous ions is more obviously improved, and after the stannous ion source is placed for 7 days, the remaining stannous ion source is more than 55% by mass; when the mass ratio of the stannous ion source to the hyaluronic acid is less than or equal to 1:1, the stability of stannous ions is improved more remarkably, and after the stannous ion source is placed for 7 days, the remaining stannous ion source is more than 75% in mass ratio.
Example 9, comparative example 3:
an oral care composition comprising stable stannous ions comprises the following ingredients in the proportions of table 5, the total amount being 100 parts to prepare a toothpaste.
Table 5:
after aging the composition products of example 9 and comparative example 3 at 40 ℃ for 30 days, the remaining stannous fluoride content of the composition solution was measured and the data is shown in table 6 below:
Table 6:
As can be seen from tables 5 and 6 above, in the toothpaste formulation containing stannous ions, the stability of stannous ions was low when hyaluronic acid was not added, and the remaining stannous ion source was less than 30% by mass after aging for 30 days at 40 ℃; when the mass ratio of the stannous ion source to the hyaluronic acid is 1:1, the stability of stannous ions is remarkably improved, and after aging for 30 days at 40 ℃, the remaining stannous ion source is still more than 75% in mass ratio.
In summary, the addition of hyaluronic acid in a specific ratio to an oral care composition containing stannous ions can greatly improve the stability of the stannous ion source in the composition.
It is to be understood that the above examples of the present invention are provided by way of illustration only and not by way of limitation of the embodiments of the present invention. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. Not all embodiments are exhaustive. All obvious changes or modifications which come within the spirit of the invention are desired to be protected.
Claims (12)
1. Use of hyaluronic acid for improving the stability of stannous ions in an oral care composition consisting of: a stannous ion source, hyaluronic acid, and an orally acceptable carrier; the method is characterized in that:
the mass ratio of the stannous ion source to the hyaluronic acid is 1:10-10:1;
The stannous ion source is added to the oral care composition in an amount of 0.05% -3%;
the addition amount of the hyaluronic acid in the oral care composition is 0.05-5%;
The mass ratio of the stannous ion source to the hyaluronic acid is 1:1-10:1;
The stannous ion source is selected from one or a combination of stannous fluoride or stannous chloride.
2. The use according to claim 1, characterized in that: the mass ratio of the stannous ion source to the hyaluronic acid is 1:3-10:1.
3. The use according to claim 1, characterized in that: the stannous ion source is added to the oral care composition in an amount of 0.1% -3%.
4. A use according to claim 3, characterized in that: the stannous ion source is added to the oral care composition in an amount of 0.5% -3%.
5. The use according to claim 4, characterized in that: the stannous ion source is added to the oral care composition in an amount of 1% -3%.
6. The use according to claim 1, characterized in that: the hyaluronic acid is added to the oral care composition in an amount of 0.1-5%.
7. The use according to claim 6, characterized in that: the hyaluronic acid is added to the oral care composition in an amount of 0.5-5%.
8. The use according to claim 7, characterized in that: the hyaluronic acid is added to the oral care composition in an amount of 1-5%.
9. The use according to claim 1, characterized in that: the molecular formula of the hyaluronic acid is (C 14H21NO11) n, and the hyaluronic acid has the following structural formula:
。
10. The use according to claim 9, characterized in that: the hyaluronic acid comprises an acid form of hyaluronic acid or a salt form of hyaluronic acid; the salt form of hyaluronic acid comprises sodium hyaluronate.
11. The use according to claim 1, characterized in that: the hyaluronic acid is selected from low molecular weight hyaluronic acid, medium molecular weight hyaluronic acid or high molecular weight hyaluronic acid;
The molecular weight of the low molecular weight hyaluronic acid ranges from 10kDa to 1000kDa; the molecular weight of the medium molecular weight hyaluronic acid ranges from 1000kDa to 1800kDa; the high molecular weight hyaluronic acid has a molecular weight range of greater than 1800kDa.
12. The use according to claim 1, characterized in that: the oral care composition comprises a toothpaste, gel, mouthwash, or tooth powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910506957.6A CN112076112B (en) | 2019-06-12 | 2019-06-12 | Oral care composition comprising stable stannous ions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910506957.6A CN112076112B (en) | 2019-06-12 | 2019-06-12 | Oral care composition comprising stable stannous ions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112076112A CN112076112A (en) | 2020-12-15 |
| CN112076112B true CN112076112B (en) | 2024-05-17 |
Family
ID=73733350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910506957.6A Active CN112076112B (en) | 2019-06-12 | 2019-06-12 | Oral care composition comprising stable stannous ions |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112076112B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112618413A (en) * | 2020-12-30 | 2021-04-09 | 重庆登康口腔护理用品股份有限公司 | Oral product containing hyaluronic acid and preparation method thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104878136A (en) * | 2015-05-20 | 2015-09-02 | 周淑华 | Leather maintenance agent and preparation method thereof |
| CN105295726A (en) * | 2015-11-11 | 2016-02-03 | 无锡英普林纳米科技有限公司 | Formaldehyde adsorption paint and preparation method thereof |
| CN105385798A (en) * | 2015-11-24 | 2016-03-09 | 仪征易力土工合成材料有限公司 | Strengthening leather care agent |
| CN105441605A (en) * | 2015-11-24 | 2016-03-30 | 仪征易力土工合成材料有限公司 | Leather maintenance agent |
| CN106039393A (en) * | 2016-06-16 | 2016-10-26 | 湖州科达化工燃料有限公司 | Anti-inflection skin adhesive |
| CN107778821A (en) * | 2016-08-31 | 2018-03-09 | 刘健文 | A kind of fiberglass-reinforced plastic and preparation method thereof |
-
2019
- 2019-06-12 CN CN201910506957.6A patent/CN112076112B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104878136A (en) * | 2015-05-20 | 2015-09-02 | 周淑华 | Leather maintenance agent and preparation method thereof |
| CN105295726A (en) * | 2015-11-11 | 2016-02-03 | 无锡英普林纳米科技有限公司 | Formaldehyde adsorption paint and preparation method thereof |
| CN105385798A (en) * | 2015-11-24 | 2016-03-09 | 仪征易力土工合成材料有限公司 | Strengthening leather care agent |
| CN105441605A (en) * | 2015-11-24 | 2016-03-30 | 仪征易力土工合成材料有限公司 | Leather maintenance agent |
| CN106039393A (en) * | 2016-06-16 | 2016-10-26 | 湖州科达化工燃料有限公司 | Anti-inflection skin adhesive |
| CN107778821A (en) * | 2016-08-31 | 2018-03-09 | 刘健文 | A kind of fiberglass-reinforced plastic and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112076112A (en) | 2020-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019200755B2 (en) | Oral care compositions | |
| RU2727658C1 (en) | Oral care compositions and methods for use thereof | |
| RU2717567C1 (en) | Compositions for oral care | |
| RU2690177C1 (en) | Oral care compositions and methods for using them | |
| TW201609161A (en) | Oral compositions containing metal ions | |
| RU2722821C2 (en) | Oral care composition | |
| JP6484181B2 (en) | Non-aqueous oral care composition | |
| EP3305275A1 (en) | Composition for oral cavity and food product, or beverage | |
| EP3071299B1 (en) | Tooth varnish compositions and methods for their use | |
| CN107468587B (en) | An oral care composition comprising stabilized polyphenols | |
| RU2739381C1 (en) | Compositions for oral care | |
| RU2723646C1 (en) | Compositions for oral care | |
| CN112076112B (en) | Oral care composition comprising stable stannous ions | |
| JPH09249541A (en) | Dentifrice | |
| MX2012009042A (en) | Antimicrobial silica composites. | |
| CN111374904B (en) | Oral care composition | |
| JPH04139118A (en) | Composition for use in oral cavity | |
| JPH05930A (en) | Composition for oral cavity | |
| JP2021095380A (en) | Dentifrice composition | |
| JP7108383B2 (en) | oral composition | |
| JPH11130643A (en) | Composition for oral cavity | |
| CN110087614B (en) | Oral care compositions | |
| JP2002255773A (en) | Composition for oral cavity | |
| JPH07187975A (en) | Composition for oral cavity | |
| CN110236977B (en) | An oral care composition comprising stabilized EGCg |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |